Ciclosporin =========== Eye drops 1 mg per mL, 2 mL SaveGeneral schedule PBS item code15541YMaximum quantity1 units Repeats5 More detailsProgramGE AdministrationAPPLICATION\_TO\_THE\_EYE Benefit typeA Brands - Vevye Dispensed price for maximum quantity (DPMQ)3 pricesVevye · Community pharmacy$77.64 Vevye · Private hospital$73.41 Vevye · Public hospital$63.28 Restrictions & indications ------------------------------ AUTHORITY REQUIRED Dry Eye Disease (Chronic, severe) - Initial treatment for up to the first 180 days of treatment Show full PBS criteriaHide full PBS criteriaChronic severe dry eye disease with keratitis Initial treatment for up to the first 180 days of treatment Patient must have a corneal fluorescein staining (CFS) grade of 4 at treatment initiation, using at least one of: (i) the Oxford scale, (ii) the modified Oxford scale, (iii) an equivalent scale to the Oxford scale as determined by the prescriber; AND Patient must have an ocular surface disease index (OSDI) score of at least 23 at treatment initiation; AND The condition must be inadequately controlled by monotherapy with a preservative free artificial tears substitute; AND The treatment must be the sole PBS-subsidised therapy for this condition; AND Patient must be undergoing simultaneous treatment with a preservative free artificial tears substitute; AND Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist; or Must be treated by an optometrist in accordance with Optometry Board of Australia guidelines; AND Patient must not be undergoing treatment with this drug under this treatment phase beyond day 180 of treatment; AND Patient must be at least 18 years of age. Prescribing instruction: State in the first authority application for this drug, for the purpose of having a baseline measurement to assess response to treatment under the Continuing treatment listing, each of: (i) the qualifying corneal fluorescein staining grade (a numerical value no less than 4), (ii) the qualifying ocular surface disease index score (a numerical value no less than 23). AUTHORITY REQUIRED Dry Eye Disease (Chronic, severe) - Continuing treatment Show full PBS criteriaHide full PBS criteriaChronic severe dry eye disease with keratitis Continuing treatment Patient must have received PBS-subsidised treatment with this drug for this condition; AND The condition must have improved to an extent that corneal fluorescein staining, using the same scale used at the time of the first authority application, shows an improvement (reduction) by at least 3 grades from baseline (the grade stated in the first authority application) - the improvement need only be demonstrated by staining once only with the first Continuing treatment authority application; AND The condition must have improved to an extent that the patient's ocular surface disease index score at the time of this authority application, has improved (reduced) by at least 30% compared to the value stated in the first authority application (i.e. baseline); AND The treatment must be the sole PBS-subsidised therapy for this condition; AND Must be treated by an ophthalmologist or by an accredited ophthalmology registrar in consultation with an ophthalmologist; or Must be treated by an optometrist in accordance with Optometry Board of Australia guidelines. Prescribing instructions: State in the first continuing treatment authority application for this drug: (i) an improved corneal fluorescein staining grade (a numerical value that has improved by 3 grades from that provided in the first Initial 1 treatment authority application). State in all continuing treatment authority applications: (ii) the ocular surface disease index score at the time of this authority application (a numerical value that is at least 30% lower than that stated in the first Initial 1 treatment authority application). Caution It is recommended that the potential for immunosuppression with long term use of this drug be clinically reviewed after at least 24 months of treatment, if not already reviewed. Notes (1)Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS) or by telephone by contacting Services Australia on 1800 888 333. Prescribing notes (2)Applications for authorisation under this restriction may be made in real time using the Online PBS Authorities system (see www.servicesaustralia.gov.au/HPOS) or by telephone by contacting Services Australia on 1800 888 333. It is recommended that the potential for immunosuppression with long term use of this drug be clinically reviewed after at least 24 months of treatment, if not already reviewed. Data source: [Australian Government PBS Schedule](https://www.pbs.gov.au/info/browse/download) · Record updated 30 September 2026. Verify current listing and prescribing requirements on the [official PBS website](https://www.pbs.gov.au/).